Table 2.
Pharmacokinetic parameters of rituximab in patients with diffuse large B‐cell lymphoma
| Parameter | Estimate | Bootstrap | ||
|---|---|---|---|---|
| Median | Nonparametric 95% confidence interval | |||
| CL1, l day–1 | 0.252 | 0.251 | 0.227 | 0.279 |
| Covariate effects on CL1 | ||||
| Age | –0.00820 | –0.00799 | –0.01449 | –0.00102 |
| Weight | 1.23 | 1.21 | 0.70 | 1.73 |
| CL2,0, l day–1 | 0.278 | 0.281 | 0.181 | 0.390 |
| KD, day−1 | 0.143 | 0.141 | 0.0478 | 0.418 |
| Covariate effects on KD | ||||
| Disease progression | –0.822 | –0.813 | –0.950 | –0.334 |
| V1, L | 4.62 | 4.62 | 4.34 | 4.93 |
| Covariate effects on V1 | ||||
| Sex | –0.214 | –0.212 | –0.296 | –0.135 |
| V2, L | 8.61 | 8.58 | 7.45 | 9.81 |
| Q, l day–1 | 1.02 | 1.01 | 0.664 | 1.95 |
| Interindividual variability | ||||
| IIVCL1 (CV% [shrinkage]) | 18.5 [5.3] | 17.2 | 11.5 | 21.8 |
| IIVKD (CV% [shrinkage]) | 161 [22.7] | 155 | 67.4 | 311 |
| IIVV1 (CV% [shrinkage]) | 11.6 [14.2] | 11.0 | 5.65 | 15.0 |
| Residual variability [shrinkage] | [6.0] | |||
| Additive, mg l–1 | 2.46 | 2.32 | 1.05 | 4.36 |
| Proportional, % | 15.9 | 15.7 | 14.3 | 17.5 |
CL1, nonspecific linear clearance; CL2,0, time‐varying specific clearance at time zero; KD, rate constant of specific clearance decay; V1, volume of the central compartment; V2, volume of the peripheral compartment; Q, distribution clearance.